Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

Cited by (152)

Items 101–152 of 152

1. Effects of NR1H3 Genetic Variation on the Expression of Liver X Receptor α and the Progression of Alzheimer's Disease
   Teemu Natunen, Henna Martiskainen, Timo Sarajärvi, Seppo Helisalmi, Juha‐Pekka Pursiheimo, Jayashree Viswanathan, Marjo H. Laitinen, Petra M. Mäkinen, Tarja Kauppinen, Tuomas H. Rauramaa et al. · 2013 · PLoS ONE
2. ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice
   Nicholas Francis Fitz, Alexis Y. Carter, Vı́ctor Tapias, Emilie L. Castranio, Ravindra B. Kodali, Iliya M. Lefterov, Radosveta P. Koldamova · 2017 · Journal of Alzheimer s Disease
3. The cell type resolved mouse transcriptome in neuron-enriched brain tissues from the hippocampus and cerebellum during prion disease
   Anna Majer, Sarah J. Medina, Debra Sorensen, Matthew J. Martin, Kathy L. Frost, Clark S. Phillipson, Kathy Manguiat, Stephanie A. Booth · 2019 · Scientific Reports
4. The novel function of bexarotene for neurological diseases
   Yangtao Liu, Pengwei Wang, Guofang Jin, Peijie Shi, Yonghui Zhao, Jiayi Guo, Yaling Yin, Qian-Hang Shao, Peng Li, Pengfei Yang · 2023 · Ageing Research Reviews
5. Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles
   Pamela A. Marshall, Peter W. Jurutka, Carl E. Wagner, Arjan van der Vaart, Ichiro Kaneko, Pedro I. Chavez, Ning Ma, Jaskaran S. Bhogal, Pritika H. Shahani, Johnathon C. Swierski et al. · 2015 · Pharmacology Research & Perspectives
6. Preclinical data reproducibility for R&D—the challenge for neuroscience
   Thomas Steckler · 2015 · Psychopharmacology
7. Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice
   Carter, Alexis Y., Letronne, Florent, Fitz, Nicholas F., Mounier, Anais, Wolfe, Cody M., Nam, Kyong Nyon, Reeves, Valerie L., Kamboh, Hafsa, Lefterov, Iliya, Koldamova, Radosveta · 2017 · PLOS ONE
8. Bexarotene Does Not Clear Amyloid Beta Plaques but Delays Fibril Growth: Molecular Mechanisms
   Pham Dinh Quoc Huy, Nguyen Quoc Thai, Zuzana Bednáriková, Le Huu Phuc, Huynh Quang Linh, Zuzana Gažová, Mai Suan Li · 2017 · ACS Chemical Neuroscience
9. New Hope from an Old Drug: Fighting Alzheimer's Disease with the Cancer Drug Bexarotene (Targretin)?
   Giorgio Aicardi · 2013 · Rejuvenation Research
10. MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease
    Yoon, Hyejin, Flores, Luis F., Kim, Jungsu · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
11. Bioactive Compound Screen for Pharmacological Enhancers of Apolipoprotein E in Primary Human Astrocytes
    Gina M. Finan, Ronald B. Realubit, Sungkwon Chung, Dieter Lütjohann, Nan Wang, John R. Cirrito, Charles Karan, Taewan Kim · 2016 · Cell chemical biology
12. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3
    Ana Carolina Valencia‐Olvera, Deebika Balu, Shreya Bellur, Thomas P. McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason M. York, Jan O. Johansson, Mary Jo LaDu et al. · 2023 · Alzheimer s Research & Therapy
13. When the dust settles: what did we learn from the bexarotene discussion?
    Ina C. Tesseur, Bart De Strooper · 2013 · Alzheimer s Research & Therapy
14. Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
    Verónica Vidal, Alba Puente, Susana García-Cerro, María Teresa García‐Unzueta, Noemı́ Rueda, Javier Riancho, Carmen Martínez‐Cué · 2021 · Frontiers in Pharmacology
15. Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
    Viswanath Das, John Holmes Miller, Alladi Charanraj Goud, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch · 2024 · Medicinal Research Reviews
16. Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its α-Helical Conformation, and Inhibits γ-Secretase Nonselectively in Liposomes
    Frits Kamp, Holger A. Scheidt, Edith Winkler, Gabriele Basset, Hannes Heinel, J.M.S. Hutchison, Loren M. LaPointe, Charles R. Sanders, Harald Steiner, Daniel Huster · 2018 · ACS Chemical Neuroscience
17. Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
    Komai, Masato, Noda, Yuka, Ikeda, Atsuya, Kaneshiro, Nanaka, Kamikubo, Yuji, Sakurai, Takashi, Uehara, Takashi, Takasugi, Nobumasa · 2024 · Journal of Lipid Research
18. Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain
    Geoffrey M. Gray, Ning Ma, Carl E. Wagner, Arjan van der Vaart · 2017 · Journal of Molecular Modeling
19. Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases
    Javier Riancho, Maria Teresa Berciano, José Berciano, Miguel Lafarga · 2016 · Journal of Neurology
20. Brain metabolite clearance: impact on Alzheimer’s disease
    Juan Manuel Zolezzi, Nibaldo C. Inestrosa · 2014 · Metabolic Brain Disease
21. Protective Effects of Bexarotene against Amyloid-β25-35-Induced Dysfunction in Hippocampal Neurons through the Insulin Signaling Pathway
    Weiwei Dai, Jiajia Yang, Ting Chen, Zhuo Ru Yang · 2014 · Neurodegenerative Diseases
22. From Neurodegeneration to Brain Health: An Integrated Approach
    Robert B. Petersen, Frances M. Lissemore, Brian Stephen Appleby, Neelum T. Aggarwal, Richard Eleftherios Boyatzis, Gemma Casadesús, Jeff Cummings, Anthony Ian Jack, George L. Perry, Jiri Safar et al. · 2015 · Journal of Alzheimer s Disease
23. Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
    Nousheen Bibi, Syed Mohd Danish Rizvi, Abida Batool, Mohammad Amjad Kamal · 2019 · Current Pharmaceutical Design
24. Parkinson's disease: a long and difficult journey.
    Georgina Casey · 2013 · PubMed
25. BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides
    Xenophon Asvos, Mohamed Ahmed El Mubarak, Theodoros Karampelas, Theodoros N Rampias, Constantin Tamvakopoulos, Gregory B. Sivolapenko, Athanasios Papakyriakou, Stavros Topouzis, Demetrios K. Vassilatis, Demosthenes Fokas · 2025 · Journal of Medicinal Chemistry
26. Bexarotene drives the self‐renewing proliferation of adult neural stem cells, promotes neuron‐glial fate shift, and regulates late neuronal differentiation
    Carolina Saibro Girardi, Ingrid Matsubara Scheibel, Lucas Fabrício da Silva Santos¹, Reykla Ramon Bittencourt, Nicole Taís Fröhlich, Luana dos Reis Possa, José Cláudio Fonseca Moreira, Daniel Pens Gelain · 2023 · Journal of Neurochemistry
27. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
    Joseph Rosenthal, Georges Belfort, David Isaacson · 2016 · PLoS ONE
28. Evaluating Novel RXR Agonists That Induce ApoE and Tyrosine Hydroxylase in Cultured Human Glioblastoma Cells
    Sanchita Mallick, Pamela A. Marshall, Carl E. Wagner, Michael C. Heck, Zhela L. Sabir, Marya S. Sabir, Christoper M. Dussik, Aleksandra Grozić, Ichiro Kaneko, Peter W. Jurutka · 2021 · ACS Chemical Neuroscience
29. Therapeutic Strategies for Neurodegenerative Diseases
    Jacques Fantini, Nouara Yahi · 2015 · Elsevier eBooks
30. Cancer drugs with high repositioning potential for Alzheimer’s disease
    Jad Majeed, Marwan Noel Sabbagh, Min H. Kang, J. Josh Lawrence, Kevin Pruitt, Sarah S. Bacus, Ellie Reyna, Maddy Brown, Boris Decourt · 2023 · Expert Opinion on Emerging Drugs
31. Synthesis of a new fluorine-18-labeled bexarotene analogue for PET imaging of retinoid X receptor
    Min Wang, Toni Davis, Mingzhang Gao, Qi‐Huang Zheng · 2014 · Bioorganic & Medicinal Chemistry Letters
32. Suppression of amyloid-β fibril growth by drug-engineered polymorph transformation
    Sima Mafimoghaddam, Yuechuan Xu, Michael B. Sherman, Elena V. Orlova, Prashant Karki, Mehmet A. Orman, Peter G. Vekilov · 2022 · Journal of Biological Chemistry
33. Nanoscale insights into the local structural rearrangements of amyloid-β induced by bexarotene
    Kamila Sofińska, Piotr Batys, Adrian Cernescu, Dhiman Ghosh, Katarzyna Skirlińska‐Nosek, Jakub Barbasz, Sara Seweryn, Natalia Wilkosz, Roland Riek, Marek Szymoński et al. · 2023 · Nanoscale
34. Bexarotene cannot reduce amyloid beta plaques through inhibition of production of amyloid beta peptides: in silico and in vitro study
    Pham Dinh Quoc Huy, Nguyen Quoc Thai, Zuzana Bednáriková, Huynh Quang Linh, Zuzana Gažová, Mai Suan Li · 2018 · Physical Chemistry Chemical Physics
35. The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
    Ezequiel Serrano, Pablo G. Sanz, Francisco José Barrantes · 2021 · Springer eBooks
36. RXR-Mediated Remodeling of Transcriptional and Chromatin Landscapes in APP Mouse Brain: Insights from Integrated Single-Cell RNA and ATAC Profiling
    Lu Yi, Xuebao Wang, Carolina Saibro Girardi, Nicholas Francis Fitz, Radosveta P. Koldamova, Iliya M. Lefterov · 2025 · Cells
37. Pathogenesis, modulation, and therapy of Alzheimer’s disease: A perspective on roles of liver-X receptors
    Jasminka Štefulj, Ute Panzenboeck, Patrick R. Hof, Goran Šimić · 2013 · Translational Neuroscience
38. Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Alzheimer’s Disease Model
    Carolina Saibro Girardi, Lu Yi, Nicholas Francis Fitz, Daniel Pens Gelain, Iliya M. Lefterov, Radosveta P. Koldamova · 2026 · International Journal of Molecular Sciences
39. Studies cast doubt on cancer drug as Alzheimer's treatment
    Helen M. Shen · 2013 · Nature
40. Cancer Chemoprevention
    Carmen Avendaño, José Carlos Menéndez · 2015 · Elsevier eBooks
41. Erratum to: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice
    Katherine D. LaClair, Kebreten F. Manaye, Dexter L. Lee, Joanne S. Allard, Alena V. Savonenko, Juan Carlos Troncoso, Philip C. Wong · 2013 · Molecular Neurodegeneration
42. Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
    Fan Liao, David M. Holtzman · 2016 · Elsevier eBooks
43. Deciphering the role of 27-hydroxycholesterol in neurodegeneration
    Muhammad Al Mustafa Ismail · 2016 · Figshare
44. Effect of liver x receptor target genes Apolipoprotein E and ATP-binding cassette transporter A1 on beta-amyloid dependent pathology in Alzheimer's disease model mice
    Alexis B. Carter · 2017 · D-Scholarship@Pitt (University of Pittsburgh)
45. Cerebral Innate Immunity
    David Gate, Terrence Town · 2016 · Elsevier eBooks
46. DEPLETION OF TDP-43 ACCELERATES NEURODEGENERATION IN AN ALZHEIMER’S MOUSE MODEL, INDEPENDENT OF BETA-AMYLOID PLAQUE BURDEN
    Katherine D. LaClair · 2016
47. Decoding the effects of Bexarotene treatment on brain of AD‐like model mice: single‐cell transcriptomics and chromatin accessibility analysis
    Yi Lu, Xuebao Wang, Carolina Saibro Girardi, Nicholas Francis Fitz, Radosveta Koldamova, Iliya Lefterov · 2025 · Alzheimer s & Dementia
48. Impact de l’infection à Helicobacter pylori sur la maladie d’Alzheimer
    Claire Roubaud Baudron · 2014 · theses.fr (ABES)
49. The role of the nicotinic receptors in prefrontal cortex spontaneous neuronal activity in the normal and diseased brain
    Fani Koukouli · 2016 · theses.fr (ABES)
50. Caractérisation du site de liaison du cholestérol sur l'APP : un modulateur de la sécrétion de peptides amyloïdes
    Linda Hanbouch · 2017 · theses.fr (ABES)
51. BindingDB Entry 50023689: BRF110, an Orally Active Nurr1-RXRα-Selective Rexinoid, Enhances BDNF Expression without Elevating Triglycerides.
    BindingDB · 2026 · UC San Diego
52. BindingDB Entry 50018264: Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.
    BindingDB · 2024 · UC San Diego